Skip Navigation


JAC Advance Access originally published online on June 23, 2009
Journal of Antimicrobial Chemotherapy 2009 64(3):667-669; doi:10.1093/jac/dkp216
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
64/3/667    most recent
dkp216v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sarfo, F. S.
Right arrow Articles by Chadwick, D. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarfo, F. S.
Right arrow Articles by Chadwick, D. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study

Fred S. Sarfo1, David F. Bibby2, Uli Schwab1, Lambert T. Appiah1, Duncan A. Clark2, Paul Collini1, Richard Phillips1, Ingrid Green2, Matthias T. Dittmar3 and David R. Chadwick4,*

1 Department of Medicine, Komfo Anokye Teaching Hospital, PO Box 1934, Kumasi, Ghana 2 Department of Virology, Barts and The London NHS Trust, London, UK 3 Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK 4 Department of Infection and Travel Medicine, The James Cook University Hospital, Middlesbrough, UK

* Corresponding author. Tel: +44-1642-854429; Fax: +44-1642-854017; E-mail: davidr.chadwick@stees.nhs.uk

Keywords: Ghana , HIV , viral load

The first 10% of the full text of this article appears below.

Sir,

HIV-2 or dual HIV-1/2 infection makes up between 4% and 24% of all HIV infections in West Africa, and dual infection ~12% of all infections in Ghana.1 HIV-2 infection progresses to AIDS more slowly than HIV-1; however, dual infection appears to progress at a rate similar to that of HIV-1.2 Antiretroviral therapy (ART) has been widely available in Ghana since 2003, with good initial results.3 Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART is first-line therapy. In many centres HIV testing has not routinely been type-specific, so patients infected . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?